Table 2.
Summary of studies correlating the Oxford classification for immunoglobulin a nephropathy with clinical outcomes
| Study | Patients (n) | End point | Univariate analysis | Multivariate analysis |
| Coppo et al[19] | 206 A, 59 C | Rate of eGFR decline | M, E, S T | M, E, S, T |
| Herzenberg et al[20] | 143 A, 44 C | Rate of eGFR decline | Not done | E, S, T |
| Katafuchi et al[21] | 702 A, C | ESRD | Not done | S, T |
| Zeng et al[22] | 1026 A | Rate of eGFR decline | M, S, T | M, T |
| Shi et al[23] | 410 A | ESRD | M, S, T | S, T |
| Edström Halling et al[24] | 99 C | GFR reduction > 50%, ESRD | M, E, T | E |
| Shima et al[25] | 161 C | eGFR < 60% mL/min per 1.73m2 | M, T | M, T |
| Coppo et al[26] | 973 A, 174 C | Rate of eGFR decline | M, E, S, T | S, T |
| Alamartine et al[27] | 183 A | Doubling of SCr or ESRD | E, S, T | None |
| El Karoui et al[28] | 128 A | Rate of eGFR decline | Not done | T |
| Lee et al[29] | 69 A | GFR reduction > 50%, ESRD | E, T | E |
| Kang et al[30] | 197 A | GFR reduction > 50%, ESRD | T | T |
| Le et al[31] | 218 C | eGFR reduction > 50%, ESRD | T, S | T |
A: Adults; C: Children; eGFR: Estimated glomerular filtration rate; E: Endothelial hypercellularity; ESRD: End-stage renal disease; GFR: Glomerular filtration rate; M: Mesangial hypercellularity; S: Segmental sclerosis; Scr: Serum creatinine; T: Tubular atrophy/interstitial fibrosis.